Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

4.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Metastasis02:30

Metastasis

5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

4.8K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.8K
Multiple Comparison Tests01:13

Multiple Comparison Tests

3.5K
Multiple comparison test, abbreviated as MCT, is a post hoc analysis generally performed after comparing multiple samples with one or more tests. An MCT will help identify a significantly different sample among multiple samples or a factor among multiple factors.
It would be easy to compare two samples using a significance alpha level of 0.05. In other words, there is only one sample pair to be compared. However, it would be difficult to identify a significantly different sample if the number...
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated analysis of mRNA and microRNA expression profiles reveals differential transcriptome signature in ischaemic and dilated cardiomyopathy induced heart failure.

Epigenetics·2020
Same author

Third Ventricle Cavernous Malformation and Obstructive Hydrocephalus Thought to Be a Colloid Cyst.

World neurosurgery·2020
Same author

Endovascular strategies for post-dissection aortic aneurysm (PDAA).

Journal of cardiothoracic surgery·2020
Same author

Stem cell-derived extracellular vesicles mitigate ageing-associated arterial stiffness and hypertension.

Journal of extracellular vesicles·2020
Same author

The ABO histo-blood group, endothelial activation, and acute respiratory distress syndrome risk in critical illness.

The Journal of clinical investigation·2020
Same author

Epstein-Barr virus infection in ulcerative colitis: a clinicopathologic study from a Chinese area.

Therapeutic advances in gastroenterology·2020

Related Experiment Video

Updated: May 6, 2026

Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk1
13:15

Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk1

Published on: February 25, 2016

12.4K

Can cMyc challenge cTn?

Qing Li1,2, Chu-Jun Yang1,2, Rui Feng1

  • 1Department of Laboratory Medicine Center, Wuhan Asia Heart Hospital Affiliated to Wuhan University of Science and Technology, Wuhan 430022, China.

Laboratory Medicine
|October 8, 2025
PubMed
Summary

Cardiac myosin-binding protein C (cMyc) offers earlier and more specific diagnosis of acute coronary syndrome than high-sensitivity cardiac troponin (hs-cTn). This biomarker shows potential to significantly improve early detection and patient outcomes.

Keywords:
acute coronary syndromecardiac troponinclinical application of cMycmyocardial myosin binding protein-C (cMyc)

More Related Videos

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

15.9K
ACT1-CUP1 Assays Determine the Substrate-Specific Sensitivities of Spliceosomal Mutants in Budding Yeast
07:31

ACT1-CUP1 Assays Determine the Substrate-Specific Sensitivities of Spliceosomal Mutants in Budding Yeast

Published on: June 30, 2022

2.9K

Related Experiment Videos

Last Updated: May 6, 2026

Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk1
13:15

Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk1

Published on: February 25, 2016

12.4K
Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

15.9K
ACT1-CUP1 Assays Determine the Substrate-Specific Sensitivities of Spliceosomal Mutants in Budding Yeast
07:31

ACT1-CUP1 Assays Determine the Substrate-Specific Sensitivities of Spliceosomal Mutants in Budding Yeast

Published on: June 30, 2022

2.9K

Area of Science:

  • Cardiology
  • Biomarker Discovery
  • Diagnostic Medicine

Background:

  • Early diagnosis of acute coronary syndrome (ACS) is crucial but challenging.
  • High-sensitivity cardiac troponin (hs-cTn) has limitations in the initial hours post-symptom onset.
  • Cardiac myosin-binding protein C (cMyc) emerges as a promising, earlier, and more specific biomarker for ACS.

Purpose of the Study:

  • To evaluate cardiac myosin-binding protein C (cMyc) as an early diagnostic biomarker for acute coronary syndrome (ACS).
  • To compare the diagnostic performance of cMyc against high-sensitivity cardiac troponin (hs-cTn).
  • To explore the utility of cMyc in various clinical settings, including myocardial infarction subtyping and heart failure.

Main Methods:

  • Comparative analyses of cMyc versus hs-cTn in multicenter studies.
  • Integration of cMyc testing into 0/1-hour diagnostic algorithms.
  • Assessment of cMyc's performance in myocardial infarction subtyping, cardiac surgery, heart failure, and prehospital settings.

Main Results:

  • Cardiac myosin-binding protein appears in circulation within 30 minutes of ischemia, peaking significantly faster than hs-cTn.
  • In non-ST-segment elevation myocardial infarction, cMyc combined with hs-cTn improved rule-out rates from 10.9% to 41.9%.
  • The cardiac-specific N-terminal fragment (C0C1f) of cMyc minimizes false positives, and point-of-care testing feasibility was demonstrated with a 70-minute turnaround.

Conclusions:

  • Cardiac myosin-binding protein demonstrates superior early diagnostic capability for ACS compared to hs-cTn.
  • cMyc has the potential to significantly transform current diagnostic paradigms for acute coronary syndrome.
  • The biomarker also shows prognostic value in heart failure and cardiac surgery contexts.